

10/12/01

**UTILITY  
PATENT APPLICATION  
TRANSMITTAL**

Form for new nonprovisional applications under 37 CFR 1.53(b)

Attorney Docket No.	2318-368
First Inventor	Jean-Marc ROCH
Title PROTEIN-PROTEIN INTERACTIONS IN NEURODEGENERATIVE DISEASES	

10/12/01  
PC 973 475072 PTO  
09/09/01

**Assignee Information:** Myriad Genetics, Inc.  
Salt Lake City, Utah

<b>APPLICATION ELEMENTS</b>  See MPEP chapter 600 concerning utility patent application contents.		ADDRESS TO: <b>Assistant Commissioner of Patents Box Patent Application Washington, D.C. 20231</b>
<p>1. <input type="checkbox"/> Fee Transmittal Form (Submit an original, and a duplicate for fee processing)</p> <p>2. <input type="checkbox"/> Applicant claims small entity status.</p> <p>3. <input checked="" type="checkbox"/> Specification Total pages [ 91 ] (preferred arrangement set forth below)</p> <ul style="list-style-type: none"> <li>- Descriptive title of the invention</li> <li>- Cross references to Related Applications</li> <li>- Statement Regarding Fed sponsored R&amp;D</li> <li>- Reference to sequence listing, a table or a computer program listing appendix</li> <li>- Background of the Invention</li> <li>- Brief Summary of the Invention</li> <li>- Brief Description of the Drawings</li> <li>- Detailed Description</li> <li>- Claims</li> <li>- Abstract of the Disclosure</li> </ul> <p><input type="checkbox"/> Drawing(s) (35 USC 113) (Total Sheets) [ ]</p> <p><input type="checkbox"/> Oath or Declaration (Total Pages) [ ]</p> <p>a. <input type="checkbox"/> Newly executed (original or copy)</p> <p>b. <input type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional with Box 17 completed)</p> <p><b><i>[Note Box 5 below]</i></b></p> <p>i <input type="checkbox"/> <b><u>DELETION OF INVENTOR(S)</u></b> Signed statement attached deleting inventor(s) named in the prior application,</p> <p>6. <input type="checkbox"/> Application Data Sheet.</p>		<p>7. <input type="checkbox"/> CD-ROM or CD-R in duplicate, large table or Computer Program</p> <p>8. Nucleotide and/or Amino Acid Sequence Submission</p> <ul style="list-style-type: none"> <li>a. <input checked="" type="checkbox"/> Computer Readable Form (CRF)</li> <li>b. Specification Sequence Listing on:           <ul style="list-style-type: none"> <li>i. <input type="checkbox"/> CD-ROM or CD-R (2 copies); or</li> <li>ii. <input checked="" type="checkbox"/> paper (5 pages)</li> </ul> </li> <li>c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</li> </ul> <p><b>ACCOMPANYING APPLICATION PARTS</b></p> <p>9. <input type="checkbox"/> Assignment Papers (cover sheet &amp; document(s))</p> <p>10. <input type="checkbox"/> 37 CFR 3.73(b) Statement (when there is an assignee)</p> <ul style="list-style-type: none"> <li><input type="checkbox"/> Power of Attorney</li> <li>11. <input type="checkbox"/> English Translation Document (if applicable)</li> <li>12. <input type="checkbox"/> Information Disclosure Statement /PTO 1449</li> <li><input type="checkbox"/> Copies of IDS Citations</li> <li>13. <input type="checkbox"/> Preliminary Amendment</li> <li>14. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) (Should be specifically itemized)</li> <li>15. <input type="checkbox"/> Certified Copy of Priority Document(s).</li> <li>16. <input type="checkbox"/> Request and Certification under 35 U.S.C. 122(b)(2)(B)(i).</li> <li>17. <input type="checkbox"/> Other:</li> </ul>

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information below or in an application Data Sheet under 37 CFR 1.76:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No.:

**Prior application information:** Examiner Group/Art Unit

For CONTINUATION OR DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.

Customer Number or Bar Code Label **6449**

Address	Rothwell, Figg, Ernst & Manbeck Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031
Name	Jeffrey L. Ihnen, Reg. No. 28,957				
Signature	<i>Jeffrey L. Ihnen</i>			Date 12 OCTOBER 2001	

**IN THE  
UNITED STATES  
PATENT AND TRADEMARK  
OFFICE**

<i>Application Number</i>	(to be assigned)
<i>Filing Date</i>	12 October 2001
<i>First Named Inventor</i>	Jean-Marc ROCH
<i>Group Art Unit</i>	
<i>Examiner Name</i>	
<i>Attorney Docket No.</i>	2318-368

*Title of the Invention:* **PROTEIN-PROTEIN INTERACTIONS  
IN NEURODEGENERATIVE DISEASES**

**STATEMENT PURSUANT TO 37 CFR 1.821(f)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

In the matter of the above-identified nonprovisional application, filed concurrently herewith, Applicants submit a computer-readable form of the sequence listing of the application. It is hereby certified that the content of the paper and computer copies of these sequences are identical.

RESPECTFULLY SUBMITTED,					
NAME AND REG. NUMBER	Jeffrey L. Ihnen, Reg. No. 28,957				
SIGNATURE			DATE	12 OCTOBER 2001	
Address	ROTHWELL, FIGG, ERNST & MANBECK, pc Suite 701-East, 555 13th Street, N.W.				
City	Washington	State	D.C.	Zip Code	20004
Country	U.S.A.	Telephone	202-783-6040	Fax	202-783-6031